戻る

Ernexa Therapeutics reports positive ERNA-201 preclinical data

  • Ernexa Therapeutics reported positive preclinical data for ERNA-201.
  • The results reinforced the company’s iMSC platform, according to Ernexa Therapeutics.
  • ERNA-101 is being advanced toward first-in-human dosing as oncology efforts accelerate.

Ernexa Therapeutics reported positive preclinical data for ERNA-201, saying the findings reinforce its iMSC platform. The company is also accelerating its oncology strategy and advancing ERNA-101 toward first-in-human dosing, an initial administration in people.

当サイトの情報はAIを用いて生成されており、正確性を保証するものではありません。 参考情報としてご活用ください。